Ionis Pharmaceuticals Sustainability Profile
Ionis Pharmaceuticals, Inc., a leading biotechnology company headquartered in the United States, is renowned for its pioneering work in RNA-targeted therapeutics. Founded in 1989, Ionis has established itself as a key player in the pharmaceutical industry, focusing on the development of innovative treatments for a range of serious diseases, including neurological disorders and cardiovascular conditions. With a robust pipeline of drugs, Ionis is particularly noted for its unique antisense technology, which allows for precise modulation of gene expression. This innovative approach has led to significant milestones, including the approval of several groundbreaking therapies. Ionis Pharmaceuticals continues to strengthen its market position through strategic partnerships and a commitment to advancing the field of genetic medicine, making it a notable force in the biopharmaceutical landscape.
DitchCarbon Score
How does Ionis Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ionis Pharmaceuticals's score of 29 is lower than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ionis Pharmaceuticals's reported carbon emissions
In 2024, Ionis Pharmaceuticals reported total Scope 1 and 2 greenhouse gas (GHG) emissions of approximately 5,146,000 kg CO2e, reflecting a 6% reduction from the previous year's emissions of about 5,483,000 kg CO2e. The company's Scope 2 emissions, primarily from purchased electricity, accounted for about 2,530,000 kg CO2e in 2024, down from approximately 2,788,000 kg CO2e in 2023. Ionis has set a near-term target to continue reducing its GHG emissions, aiming for a further 6% decrease in both Scope 1 and 2 emissions by the end of 2024 compared to 2023 levels. This commitment underscores the company's dedication to climate action and sustainability. The emissions data is not cascaded from any parent organization, indicating that Ionis Pharmaceuticals, Inc. independently reports its emissions and climate initiatives. The company has not disclosed any Scope 3 emissions data, which typically includes indirect emissions from the supply chain and product use. Overall, Ionis Pharmaceuticals is actively working towards reducing its carbon footprint, aligning with industry standards for climate responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 2,566,000,000 | - | - | - |
| Scope 2 | 2,052,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - |
How Carbon Intensive is Ionis Pharmaceuticals's Industry?
How Carbon Intensive is Ionis Pharmaceuticals's Location?
Ionis Pharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ionis Pharmaceuticals has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
